S3525 Recurrent Carbohydrate Antigen 19-9 Elevation Associated With Marijuana Use: A Benign Mimicker of Pancreatic Malignancy

Introduction: Carbohydrate Antigen 19-9 (CA 19-9) is a serum tumor marker commonly used to assess pancreatic malignancy. However, benign elevations can occur. We present a case of recurrent CA 19-9 elevation temporally associated with marijuana use, with normalization upon cessation. Case Description/Methods: A 49-year-old man with hypertension and chronic marijuana use was referred for elevated CA 19-9 following abdominal pain. Vitals were stable; exam revealed a non-tender abdomen with normoactive bowel sounds. Labs: WBC 7.4 × 10³/μL, hemoglobin 15.9 g/dL, ALP 59 U/L, AST 36 U/L, ALT 31 U/L, total bilirubin 0.7 mg/dL, and normal renal function. CA 19-9 measured 61.43 U/mL. Magnetic resonance cholangiopancreatography (MRCP) showed normal pancreatic and biliary anatomy. Endoscopic ultrasound (EUS) revealed diffuse parenchymal atrophy, hyperechoic strands, and lobularity without calcifications, masses, or honeycombing. He was advised to stop cannabis. Three months later, CA 19-9 decreased to 55.05 U/mL. At 1-year follow-up, CA 19-9 rose to 78.49 U/mL. The patient admitted to resuming marijuana use. Repeat EUS and pancreatic biopsy revealed no new findings and no dysplasia. The CA 19-9 elevation was attributed to cannabis exposure. Social work support was engaged for cessation counseling. Discussion: This case illustrates a reversible, benign CA 19-9 elevation associated with marijuana use. While typically linked to pancreatic adenocarcinoma, CA 19-9 can rise in conditions such as cholestasis, pancreatitis, cirrhosis, or fibrosis. Potential mechanisms include inflammation-driven secretion, impaired clearance, or cannabinoid receptor-mediated modulation of pancreatic and hepatic activity. Tetrahydrocannabinol (THC) interacts with CB1 and CB2 receptors in the pancreas and liver, potentially affecting immune tone, enzymatic activity, and bile secretion. In this case, biomarker trends closely mirrored marijuana use, suggesting a possible causative relationship. Awareness of such benign causes is essential to avoid unnecessary invasive testing. Further research is needed to clarify the dose-effect relationship and underlying biochemical mechanisms.

Authors

Publication Details

Journal
The American Journal of Gastroenterology
Published
2025-10-01
DOI
https://doi.org/10.14309/01.ajg.0001141560.74310.b1
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

S3525 Recurrent Carbohydrate Antigen 19-9 Elevation Associated With Marijuana Use: A Benign Mimicker of Pancreatic Malignancy

Fazel Dinary, Pearl Aggarwal, Niloufar Alimohammadi, Sara Saleh et al.
The American Journal of Gastroenterology
Pancreatic and Hepatic Oncology Research
article

S3525 Recurrent Carbohydrate Antigen 19-9 Elevation Associated With Marijuana Use: A Benign Mimicker of Pancreatic Malignancy

Fazel Dinary, Pearl Aggarwal, Niloufar Alimohammadi, Sara Saleh, Ibrahim Maghari, Farah A. Khraisat, Saqr Alsakarneh, Fatema Dinary
article en

Abstract

Introduction: Carbohydrate Antigen 19-9 (CA 19-9) is a serum tumor marker commonly used to assess pancreatic malignancy. However, benign elevations can occur. We present a case of recurrent CA 19-9 elevation temporally associated with marijuana use, with normalization upon cessation. Case Description/Methods: A 49-year-old man with hypertension and chronic marijuana use was referred for elevated CA 19-9 following abdominal pain. Vitals were stable; exam revealed a non-tender abdomen with normoactive bowel sounds. Labs: WBC 7.4 × 10³/μL, hemoglobin 15.9 g/dL, ALP 59 U/L, AST 36 U/L, ALT 31 U/L, total bilirubin 0.7 mg/dL, and normal renal function. CA 19-9 measured 61.43 U/mL. Magnetic resonance cholangiopancreatography (MRCP) showed normal pancreatic and biliary anatomy. Endoscopic ultrasound (EUS) revealed diffuse parenchymal atrophy, hyperechoic strands, and lobularity without calcifications, masses, or honeycombing. He was advised to stop cannabis. Three months later, CA 19-9 decreased to 55.05 U/mL. At 1-year follow-up, CA 19-9 rose to 78.49 U/mL. The patient admitted to resuming marijuana use. Repeat EUS and pancreatic biopsy revealed no new findings and no dysplasia. The CA 19-9 elevation was attributed to cannabis exposure. Social work support was engaged for cessation counseling. Discussion: This case illustrates a reversible, benign CA 19-9 elevation associated with marijuana use. While typically linked to pancreatic adenocarcinoma, CA 19-9 can rise in conditions such as cholestasis, pancreatitis, cirrhosis, or fibrosis. Potential mechanisms include inflammation-driven secretion, impaired clearance, or cannabinoid receptor-mediated modulation of pancreatic and hepatic activity. Tetrahydrocannabinol (THC) interacts with CB1 and CB2 receptors in the pancreas and liver, potentially affecting immune tone, enzymatic activity, and bile secretion. In this case, biomarker trends closely mirrored marijuana use, suggesting a possible causative relationship. Awareness of such benign causes is essential to avoid unnecessary invasive testing. Further research is needed to clarify the dose-effect relationship and underlying biochemical mechanisms.

The American Journal of GastroenterologyVol. 120(10S2)
Openalex Percentile: Top 58%
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.